Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Venetoclax is a novel oral small molecule drug that targets the BCL-2 protein to kill cancer cells by inducing the endogenous apoptotic pathway of tumor cells. In addition to AML, ···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：411
Venetoclax is a small molecule drug that targets BCL-2 and is able to promote normal apoptosis of cancer cells by blocking the BCL-2 protein. Overexpression of BCL-2 protein in can···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：300
Venetoclax is an oral anticancer drug targeting BCL-2 that promotes apoptosis of tumor cells by inhibiting the activity of BCL-2 protein. In China, venetoclax has been approved for···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：238
By binding to BCL-2 protein, venetoclax inhibits the obstruction of apoptosis of tumor cells and effectively kills cancer cells. Venetoclax was approved by the NMPA in 2020 for the···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：303
Venetoclax is a small molecule drug approved in combination with azacitidine for the treatment of acute myeloid leukemia. Initially indicated as chronic lymphocytic leukemia, it ha···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：290
Venetoclax is an oral targeted drug that can effectively inhibit the anti-apoptotic function of BCL-2 protein and restore the normal death of cancer cells. The drug is usually used···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：355
Venetoclax is a targeted drug used in the treatment of a variety of hematologic malignancies, mainly by blocking the activity of BCL-2 protein to promote apoptosis of tumor cells. ···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：315
Venetoclax is the only approved selective inhibitor of Bcl-2 in the world. By binding Bcl-2 protein with high affinity, Bax/Bak-dependent apoptosis is induced and platelet damage i···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：304
As a potent and selective oral inhibitor targeting FGFR subtypes 1/2/3, Pemigatinib provides a new treatment option for cholangiocarcinoma patients.What is the dosage of Pemigatini···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：216
Pemigatinib, brand name Damitan, is a potent and selective oral inhibitor against FGFR subtypes 1/2/3.How to use PemigatinibPemigatinibtablets should be swallowed whole, not chewed···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：213
Pemigatinibis a small molecule kinase inhibitor targeting the fibroblast growth factor receptor (FGFR), primarily for the treatment of advanced or metastatic cholangiocarcinoma cau···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：300
Pemigatinib is indicated for adult patients with advanced, metastatic, or unresectable cholangiocarcinoma with FGFR2 fusion or rearrangement confirmed by testing.What are the suita···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：285
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2272025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4532024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2332025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2462025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2552025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2352025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2172025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
